Prestige Biopharma CEO Soyeon Park Purchases Approximately 70,000 Additional Shares, Bringing Total Purchases to 161,765 Shares

Prestige Biopharma CEO Soyeon Park has made an additional purchase of company shares, once again demonstrating her commitment to responsible management. Following her recent purchase of approximately 97,000 shares, CEO Park acquired another 70,000 shares, bringing the total number of shares purchased to 161,765. 

Following the latest transaction, CEO Park’s total shareholding increased to 9,418,045 shares, representing a 15.67% stake in the company. Her continued share purchases are seen as a demonstration of her commitment to strengthening shareholder confidence and restoring the company’s corporate value. 

 

“I decided to make this additional purchase based on my belief that the company’s current share price is undervalued relative to its intrinsic value, as part of my efforts to strengthen shareholder confidence and demonstrate responsible management,” said Lisa Soyeon Park, CEO of Prestige Biopharma. 

 

“We will continue to make every effort to enhance corporate value and maximize shareholder value by successfully commercializing our biosimilars globally and delivering meaningful progress in our innovative drug development programs,” she added.